PagerDuty's stock drops on tepid guidance amid 'headwinds from small business'
By Jon Swartz
PagerDuty Inc.'s stock tumbled 9% in after-hours trading Thursday following quarterly results that slightly edged analyst estimates but offered tepid guidance.
"The quarter was characterized by strong momentum in the midmarket and enterprise," Howard Wilson, the cloud-computing company's chief financial officer, said in an interview. "We still see headwinds from small business, but our [annual recurring revenue] was 62% from customers using two or more of our products."
PagerDuty (PD) reported a fiscal fourth-quarter net loss of $28.8 million, or 33 cents a share, compared with a net loss of $25 million, or 27 cents a share, in the year-prior quarter. Adjusted earnings were 17 cents a share.
Revenue climbed 10% to $111.1 million, from $100.97 million in the year-prior quarter.
Analysts surveyed by FactSet had expected, on average, adjusted net income of 15 cents a share on revenue of $110.7 million.
PagerDuty provided first-quarter sales guidance of between $110.5 million and $112.5 million. FactSet analysts were forecasting $113.9 million.
Shares of PagerDuty have sunk 28% over the last 12 months. The broader S&P 500 index SPX is up 30% in that time.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-14-24 2008ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks